Adenoviral Infections in Singapore: Should New Antiviral Therapies and Vaccines Be Adopted?
Adenovirus Infections, Human
/ diagnosis
Adenovirus Vaccines
/ immunology
Adenoviruses, Human
/ genetics
Adolescent
Adult
Antiviral Agents
/ therapeutic use
Child
Child, Preschool
DNA, Viral
/ genetics
Diagnostic Tests, Routine
/ methods
Disease Outbreaks
/ prevention & control
Female
Genotype
Humans
Infant
Male
Middle Aged
Phylogeny
Prospective Studies
Respiratory Tract Infections
/ drug therapy
Retrospective Studies
Risk Factors
Severity of Illness Index
Singapore
/ epidemiology
Whole Genome Sequencing
adenovirus
genotyping
molecular epidemiology
pediatric disease
respiratory disease
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
03 02 2020
03 02 2020
Historique:
received:
14
08
2019
accepted:
25
09
2019
pubmed:
30
9
2019
medline:
22
9
2020
entrez:
30
9
2019
Statut:
ppublish
Résumé
A number of serious human adenovirus (HAdV) outbreaks have been recently reported: HAdV-B7 (Israel, Singapore, and USA), HAdV-B7d (USA and China), HAdV-D8, -D54, and -C2 (Japan), HAdV-B14p1 (USA, Europe, and China), and HAdV-B55 (China, Singapore, and France). To understand the epidemiology of HAdV infections in Singapore, we studied 533 HAdV-positive clinical samples collected from 396 pediatric and 137 adult patients in Singapore from 2012 to 2018. Genome sequencing and phylogenetic analyses were performed to identify HAdV genotypes, clonal clusters, and recombinant or novel HAdVs. The most prevalent genotypes identified were HAdV-B3 (35.6%), HAdV-B7 (15.4%), and HAdV-E4 (15.2%). We detected 4 new HAdV-C strains and detected incursions with HAdV-B7 (odds ratio [OR], 14.6; 95% confidence interval [CI], 4.1-52.0) and HAdV-E4 (OR, 13.6; 95% CI, 3.9-46.7) among pediatric patients over time. In addition, immunocompromised patients (adjusted OR [aOR], 11.4; 95% CI, 3.8-34.8) and patients infected with HAdV-C2 (aOR, 8.5; 95% CI, 1.5-48.0), HAdV-B7 (aOR, 3.7; 95% CI, 1.2-10.9), or HAdV-E4 (aOR, 3.2; 95% CI, 1.1-8.9) were at increased risk for severe disease. Singapore would benefit from more frequent studies of clinical HAdV genotypes to identify patients at risk for severe disease and help guide the use of new antiviral therapies, such as brincidofovir, and potential administration of HAdV 4 and 7 vaccine.
Sections du résumé
BACKGROUND
A number of serious human adenovirus (HAdV) outbreaks have been recently reported: HAdV-B7 (Israel, Singapore, and USA), HAdV-B7d (USA and China), HAdV-D8, -D54, and -C2 (Japan), HAdV-B14p1 (USA, Europe, and China), and HAdV-B55 (China, Singapore, and France).
METHODS
To understand the epidemiology of HAdV infections in Singapore, we studied 533 HAdV-positive clinical samples collected from 396 pediatric and 137 adult patients in Singapore from 2012 to 2018. Genome sequencing and phylogenetic analyses were performed to identify HAdV genotypes, clonal clusters, and recombinant or novel HAdVs.
RESULTS
The most prevalent genotypes identified were HAdV-B3 (35.6%), HAdV-B7 (15.4%), and HAdV-E4 (15.2%). We detected 4 new HAdV-C strains and detected incursions with HAdV-B7 (odds ratio [OR], 14.6; 95% confidence interval [CI], 4.1-52.0) and HAdV-E4 (OR, 13.6; 95% CI, 3.9-46.7) among pediatric patients over time. In addition, immunocompromised patients (adjusted OR [aOR], 11.4; 95% CI, 3.8-34.8) and patients infected with HAdV-C2 (aOR, 8.5; 95% CI, 1.5-48.0), HAdV-B7 (aOR, 3.7; 95% CI, 1.2-10.9), or HAdV-E4 (aOR, 3.2; 95% CI, 1.1-8.9) were at increased risk for severe disease.
CONCLUSIONS
Singapore would benefit from more frequent studies of clinical HAdV genotypes to identify patients at risk for severe disease and help guide the use of new antiviral therapies, such as brincidofovir, and potential administration of HAdV 4 and 7 vaccine.
Identifiants
pubmed: 31563943
pii: 5576003
doi: 10.1093/infdis/jiz489
pmc: PMC7107482
doi:
Substances chimiques
Adenovirus Vaccines
0
Antiviral Agents
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
566-577Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Am J Hyg. 1958 Sep;68(2):95-105
pubmed: 13571224
Front Microbiol. 2018 Sep 11;9:2178
pubmed: 30254627
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Emerg Infect Dis. 2012 Mar;18(3):507-9
pubmed: 22377242
J Infect Dis. 1999 Jun;179(6):1531-3
pubmed: 10228076
J Clin Microbiol. 2005 Jul;43(7):3083-94
pubmed: 16000418
J Trop Pediatr. 2004 Oct;50(5):279-84
pubmed: 15510759
Biol Blood Marrow Transplant. 2012 May;18(5):731-8
pubmed: 21963623
J Thorac Dis. 2018 Jul;10(Suppl 19):S2280-S2294
pubmed: 30116607
Clin Infect Dis. 2007 Nov 1;45(9):1120-31
pubmed: 17918073
Biol Blood Marrow Transplant. 2017 Mar;23(3):512-521
pubmed: 28063938
Blood. 2017 Apr 6;129(14):2033-2037
pubmed: 28153824
Cell. 1984 May;37(1):309-19
pubmed: 6722875
J Clin Virol. 2009 Sep;46(1):80-4
pubmed: 19577957
Microbiol Immunol. 2013 Aug;57(8):553-60
pubmed: 23734976
J Virol. 2005 Feb;79(4):2559-72
pubmed: 15681456
Trans R Soc Trop Med Hyg. 2015 Jul;109(7):433-9
pubmed: 26038572
Viruses. 2019 Jan 31;11(2):
pubmed: 30708990
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Jpn J Infect Dis. 2016 Nov 22;69(6):500-504
pubmed: 27000448
Emerg Infect Dis. 2012 Nov;18(11):1825-32
pubmed: 23092602
Emerg Infect Dis. 2012 May;18(5):852-4
pubmed: 22515984
New Microbiol. 2006 Jul;29(3):177-84
pubmed: 17058784
Ann Acad Med Singapore. 2015 Feb;44(2):50-9
pubmed: 25797817
Emerg Infect Dis. 2015 Jul;21(7):1192-6
pubmed: 26079293
Virus Evol. 2015 May 26;1(1):vev003
pubmed: 27774277
Int J Infect Dis. 2018 Oct;75:89-91
pubmed: 30144556
J Med Virol. 2017 Aug;89(8):1387-1394
pubmed: 28198541
Br J Ophthalmol. 1982 Dec;66(12):776-80
pubmed: 6293531
Sci Rep. 2017 Nov 13;7(1):15380
pubmed: 29133946
Clin Infect Dis. 2014 Oct;59(7):962-8
pubmed: 24991024
Emerg Microbes Infect. 2018 Dec 5;7(1):200
pubmed: 30514848
BMC Infect Dis. 2018 Mar 20;18(1):135
pubmed: 29558885
J Virol. 1982 Nov;44(2):530-7
pubmed: 7143575
Emerg Infect Dis. 2018 Feb;24(2):201-209
pubmed: 29350143
Front Public Health. 2018 Apr 09;6:104
pubmed: 29686984
J Infect Dis. 2020 Feb 18;221(5):685-686
pubmed: 30753651
Proc Soc Exp Biol Med. 1954 Jan;85(1):183-8
pubmed: 13134329
Medicine (Baltimore). 2016 May;95(18):e3577
pubmed: 27149483
Virology. 2013 Sep 1;443(2):197-207
pubmed: 23763770
PLoS One. 2018 Oct 15;13(10):e0205795
pubmed: 30321228
J Clin Microbiol. 2000 Nov;38(11):4114-20
pubmed: 11060077
Semin Respir Crit Care Med. 2016 Aug;37(4):586-602
pubmed: 27486739
Open Forum Infect Dis. 2017 Mar 25;4(2):ofx053
pubmed: 28491891
J Infect Dis. 2010 Jul 1;202(1):93-103
pubmed: 20500088
Mol Biol Evol. 2009 Jul;26(7):1641-50
pubmed: 19377059
J Infect Dis. 1979 Jul;140(1):42-7
pubmed: 222852
Sci Rep. 2014 Dec 08;4:7365
pubmed: 25482188